Lucid Diagnostics’ (LUCD) “Sell (E+)” Rating Reaffirmed at Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of Lucid Diagnostics (NASDAQ:LUCD) in a research note issued to investors on Tuesday morning,Weiss Ratings reports.

Other equities analysts also recently issued research reports about the stock. Wall Street Zen raised shares of Lucid Diagnostics from a “sell” rating to a “hold” rating in a research note on Tuesday. BTIG Research boosted their price objective on shares of Lucid Diagnostics from $2.00 to $2.50 and gave the stock a “buy” rating in a research note on Friday, September 5th. Needham & Company LLC reissued a “buy” rating and issued a $3.00 price objective on shares of Lucid Diagnostics in a research note on Wednesday, August 13th. Finally, Ascendiant Capital Markets boosted their price objective on shares of Lucid Diagnostics from $7.75 to $8.00 and gave the stock a “buy” rating in a research note on Monday, October 6th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Lucid Diagnostics has an average rating of “Moderate Buy” and a consensus price target of $3.70.

Lucid Diagnostics Stock Performance

Shares of NASDAQ LUCD opened at $1.19 on Tuesday. The firm has a market capitalization of $158.84 million, a price-to-earnings ratio of -1.00 and a beta of 1.19. The stock has a 50 day moving average price of $1.10 and a 200 day moving average price of $1.20. Lucid Diagnostics has a 52-week low of $0.75 and a 52-week high of $1.80.

Insider Activity

In other news, Director Dennis Matheis bought 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The shares were purchased at an average cost of $1.02 per share, with a total value of $102,000.00. Following the transaction, the director directly owned 665,443 shares in the company, valued at approximately $678,751.86. The trade was a 17.69% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 6.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Lucid Diagnostics

Hedge funds have recently made changes to their positions in the company. Quadrature Capital Ltd acquired a new position in shares of Lucid Diagnostics in the 2nd quarter valued at $29,000. Berkshire Asset Management LLC PA acquired a new position in shares of Lucid Diagnostics in the 1st quarter valued at $30,000. Traphagen Investment Advisors LLC acquired a new position in shares of Lucid Diagnostics in the 2nd quarter valued at $34,000. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Lucid Diagnostics in the 1st quarter valued at $37,000. Finally, JPMorgan Chase & Co. increased its position in shares of Lucid Diagnostics by 71,026.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company’s stock valued at $38,000 after acquiring an additional 32,672 shares during the period. 74.01% of the stock is owned by institutional investors and hedge funds.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.